Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer

BACKGROUND: Aromatase inhibitor (AI) is a cornerstone drug for endocrine therapy of postmenopausal hormone receptor-positive breast cancer. The relationship between AI medication and subsequent cataract risk is yet inconclusive. METHODS: A total of 1,697 postmenopausal, early-staged, and hormone rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Han, Shao, Zhi-Ming, Yu, Ke-Da, Xu, Ge-Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186723/
https://www.ncbi.nlm.nih.gov/pubmed/32355786
http://dx.doi.org/10.21037/atm.2020.02.112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186723/
https://www.ncbi.nlm.nih.gov/pubmed/32355786
http://dx.doi.org/10.21037/atm.2020.02.112

Ejemplares similares